Senior Management Led | Transactions
Predictive Therapeutics Has Issued 5,000,000 Shares of Series A Preferred Stock
Has Issued 5,000,000 Shares of Series A Preferred Stock
About Predictive Therapeutics
Predictive Therapeutics is a clinical stage oncology company, with a focus on immunotherapy. We seek to acquire undervalued late stage assets for clinical development. Our goal is to unlock the potential of these promising cancer therapies in order to bring effective and safe drugs to patients.
Contact Us for More Information
Would you like to learn more about working with Outcome Capital or discuss your specific needs?
© Outcome Capital 2024. Member of Financial Industry Regulatory Authority (FINRA) and the Securities Investment Protection Corporation (SIPC). Check the background of this firm on FINRA’s BrokerCheck.
Business Continuity Plan | Privacy Policy | Regulation Best Interest
